Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1211 in advanced solid tumors
NCT05065710Phase 1Completed
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ZL-1211 in solid tumor (advanced stage). Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose at 1 month, Safety and Tolerability and 1 more. Started Jan 2022; status: completed.
02
Drugs
ZL-1211
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05065710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065710.